Manumycin A Attenuates DSS-Induced Colitis in Mice via Anti-Inflammatory Effects Following Intraperitoneal...

Area of Science:

• Pharmacology
• Gastroenterology
• Immunology

Background:

• Manumycin A, a polyketide antibiotic, exhibits anti-inflammatory and immunomodulatory properties.
• Its therapeutic potential in inflammatory bowel disease (IBD) remains unexplored.
• This study investigates Manumycin A's efficacy in a dextran sulfate sodium (DSS)-induced colitis model.

Purpose of the Study:

• To evaluate the protective effects of Manumycin A in a DSS-induced colitis mouse model.
• To assess Manumycin A's impact on inflammatory markers and colonic tissue damage.
• To determine the therapeutic potential of Manumycin A for IBD treatment.

Main Methods:

• Experimental colitis induced in mice using 3% DSS.
• Administration of Manumycin A (1, 5, 10 mg/kg) or 5-aminosalicylic acid (positive control).
• Evaluation of disease severity via body weight, disease activity index (DAI), colon length, histopathology, and cytokine analysis (IL-1β, IL-6, TNF-α, IFN-γ).

Main Results:

• Manumycin A significantly reduced DAI scores and alleviated colon shortening in a dose-dependent manner.
• Histopathological analysis revealed improved epithelial damage, mucosal integrity, and reduced inflammatory cell infiltration.
• Immunohistochemistry confirmed decreased expression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, IFN-γ) in colon tissues.

Conclusions:

• Manumycin A exerts protective effects against DSS-induced colitis.
• It attenuates inflammatory responses and ameliorates colonic tissue damage.
• Manumycin A shows promise as a potential therapeutic agent for IBD.